The Swedish group BICO, which was formerly Cellink, takes hold of Biosero, a leading provider of software for automated workflows and lab connectivity. The $ 165 million acquisition will enable BICO to offer fully automated and connected workflow solutions from its current portfolio, as well as with software solutions from Biosero.
Biosero is based in San Diego and employs 75 people. The company offers software solutions that enable seamless lab automation for connected and intelligent workflows. These solutions are expected to have a significant impact on the entire core industrial ecosystem of BICO in terms of cell line development, multi-omics, tissue engineering and diagnostics.
BICO said these “inter-company synergies have the potential to unlock important orders related to automated workflows.” Following the acquisition, BICO announced its intention to invest $ 20 million over three years to accelerate Biosero’s business program to expand into new geographic markets.
“At BICO, we are committed to leveraging our bioconvergence technologies to develop intelligent, automated and sustainable solutions for our customers, and thus revolutionize the healthcare sector. With Biosero, we are taking an important and strategic step in expanding our portfolio with intelligent combinatorial software systems to enable automated workflows, ”said Erik Gatenholm, CEO and co-founder of BICO in a statement. “The Biosero software platform will serve as the glue to our impressive portfolio of instruments and hardware solutions, combining the excellent hardware technologies we have acquired over the years. Through improved effectiveness and efficiency, this leads to better and faster decision-making for our customers and helps solve the modern healthcare challenges we face.
Elsewhere in the world:
Métrion Biosciences – Based in the United Kingdom, Metrion Biosciences Limited and Bioqube Ventures, based in Belgium, a European investment company specializing in life sciences, have entered into a collaboration supported by Bioqube Factory Fund I, to incubate a research project on the discovery of drugs targeting autoimmune diseases. Bioqube and Metrion will advance a series of previously identified highly potent and selective small molecule inhibitors of the human potassium ion channel Kv1.3 to enable further development. Activation of this voltage-gated ion channel in effector memory T cells is considered an early and necessary step in the development of autoimmune diseases, including rheumatoid arthritis, lupus nephritis, psoriasis, multiple sclerosis and many others.
Limited mesoblast – Australia-based Mesoblast received comments from the United States Food and Drug Administration regarding a planned Phase III study of rexlemestrocel-L in patients with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to available therapies, including opioids. In the United States, there is excessive opioid use in this patient population, with over 50% of opioid prescriptions in the United States for the treatment of chronic low back pain. Treatment with non-opioid drugs continues to be an unmet medical need and priority. A key goal is to demonstrate reduction in pain and opioid use and to position rexlemestrocel-L as a potential opioid sparing agent.
UCB – The Belgian company UCB announced the positive results of the interim analysis of the phase III BE MOBILE 2 study, which evaluates the efficacy and safety of bimekizumab in adults with active ankylosing spondylitis. The BE MOBILE 2 study met its primary endpoint, as measured by the proportion of patients who achieved the SpondyloArthritis International Society Response Assessment 40 (ASAS40) at 16 weeks. The ASAS40 improvement was 40% from baseline. The study also met all ranked secondary endpoints, including significant improvements with bimekizumab versus placebo at week 16 in patient-reported disease activity and nocturnal spinal pain score. BE MOBILE 2 is one of two Phase III studies evaluating bimekizumab across the spectrum of axial spondylitis (axSpA), which includes both ankylosing spondylitis and non-radiographic (nr) -axSpA.
Variational AI – Vancouver-based Variational AI has partnered with UBC and adMare BioInnovations to develop a novel SARS-CoV-2 major protease inhibitor (3CLpro) as potential against all variants of concern . The COVID-19 Drug Discovery Program is funded by the Digital Technology Supercluster of Canada, which is supported by the Canadian Department of Innovation, Science and Industry.
Xeltis – Based in the Netherlands, medical technology company Xeltis has announced that it has implanted the very first synthetic access restorative grafts for hemodialysis in patients. The company said several patients with renal failure or advanced renal failure requiring dialysis have been successfully implanted with aXess transplants in a first European human trial. AXess grafts allow early puncture, or initiation of dialysis, soon after implantation. Over time, they are designed to transform into living blood vessels, as their porous microstructure is colonized by the patient’s own tissues.
Ji Xing Pharmaceuticals Limited – Ji Xing and Cytokinetics, based in China, have expanded an ongoing collaboration to develop and commercialize omecamtiv mecarbil for the proposed treatment of heart failure with reduced ejection fraction (HFrEF) in Greater China.
ITM isotope – Based in Germany, ITM Isotope Technologies Munich SE and the Australian Nuclear Science and Technology Organization have extended their partnership by entering into a long-term license agreement that will allow ANSTSO to continue producing nca177 Lu for the Australian markets and New Zealanders using ITM’s unique production technology. Nca177 Lu is used as a radiopharmaceutical precursor in targeted radionuclide therapy, a new treatment regimen in precision oncology.
Osivax – French company Osivax has announced promising results from a phase IIa study of OVX876, a broad-spectrum influenza vaccine candidate. OVX836 targets the internal nucleoprotein (NP), a highly conserved antigen that is much less susceptible to mutations and would potentially provide universal protection. OVX836 exhibited an excellent safety profile at all dose levels tested and demonstrated a strong and durable NP-specific cellular immune response following intramuscular injection. Although the study was not designed to measure clinical efficacy, an initial protective signal against influenza symptoms in the 180 µg arm was observed, the company said.
Menarini Group– Menarini, based in Italy, has authorized Nexpovio from Karyopharm Therapeutics, a first-class oral selective nuclear export inhibitor (SINE) compound. Menarini has received exclusive marketing rights from Nexpovio for the treatment of oncology indications in the European Union and other European countries, including the United Kingdom, Latin America and other key countries. In return, Karyopharm will receive an upfront payment of $ 75 million and is eligible to receive up to an additional $ 202.5 million in future stages.
Gédéa Biotech – The Swedish women’s health company Gedea Biotech has announced that it has received funding for a research project with the Center for Translational Microbiome Research at Karolinska Institutet (KI), for its flagship product, pHyph, a vaginal tablet for the topical treatment of bacterial vaginosis (BV). The objective of the project is to better understand the microbial etiology of bacterial vaginosis (BV) and the factors associated with the success of treatment without antibiotics with pHyphen.
Avacta Group – UK group Avacta said its AffiDX SARS-CoV-2 antigen lateral flow test has been CE marked for use as a consumer self-test in the UK and EU. AffiDX SARS-CoV-2 Antigen Lateral Flow Autotest will be marketed by Medusa Healthcare under the brand name “MeduFlow”.